Johnson & Johnson (JNJ)vsViemed Healthcare Inc (VMD)
JNJ
Johnson & Johnson
$265.58
-0.29%
HEALTHCARE · Cap: $640.02B
VMD
Viemed Healthcare Inc
$8.79
+0.46%
HEALTHCARE · Cap: $345.84M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 32369% more annual revenue ($97.93B vs $301.61M). JNJ leads profitability with a 21.5% profit margin vs 4.8%. VMD appears more attractively valued with a PEG of 1.86. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
VMD
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$265.58
$125.01 premium
Margin of Safety
+27.3%
Fair Value
$11.62
Current Price
$8.79
$2.83 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Revenue surging 23.9% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Expensive relative to growth rate
Moderate valuation
Smaller company, higher risk/reward
4.8% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : VMD
The strongest argument for VMD centers on Debt/Equity, Altman Z-Score, Price/Book. Revenue growth of 23.9% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : VMD
The primary concerns for VMD are PEG Ratio, P/E Ratio, Market Cap. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
JNJ profiles as a mature stock while VMD is a growth play — different risk/reward profiles.
VMD carries more volatility with a beta of 1.09 — expect wider price swings.
VMD is growing revenue faster at 23.9% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 52/100), backed by strong 21.5% margins. VMD offers better value entry with a 27.3% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Viemed Healthcare Inc
HEALTHCARE · MEDICAL DEVICES · USA
Viemed Healthcare, Inc. provides durable home medical equipment and post-acute respiratory health care services to patients in the United States. The company is headquartered in Lafayette, Louisiana.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?